Infantile Hemangioma With Minimal or Arrested Growth : Epidemiology, Clinical Characteristics and Evolution

Comparing Epidemiological and Clinical Characteristics of Infantile Hemangioma With Minimal or Arrested Growth (IH-MAG) and Classic Infantile Hemangioma : a Retrospective Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05080868

Enrollment

224

Registered

2021-10-18

Start date

2021-03-23

Completion date

2021-08-15

Last updated

2021-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemangioma, Capillary

Brief summary

Infantile hemangioma (IH) is the most common vascular tumor of infancy, characterized by its clinical history. Absent at birth or present under the form of a premonitory mark, they display a rapid proliferative phase starting in the first weeks of life. Then, after a plateau phase, they slowly involute. However, a subtype of IH named abortive, minimal or arrested growth, reticular or telangiectatic hemangioma differs from typical IH because it doesn't have a proliferative component, or only a minimal one. This subtype of hemangioma has been recently described and data are lacking regarding its proportion among infantile hemangioma and its differences with classic infantile hemangioma. The aim of this study is to estimate the proportion of abortive hemangioma among infantile hemangioma. Also, the investigators aim to compare the clinical characteristics of classic infantile hemangiomas and abortive hemangiomas. Lastly, investigators wished to study the evolution of abortive hemangioma.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Days to 18 Years

Healthy volunteers

Yes

Inclusion criteria

* Children between 0 and 18 years old * Followed in the dermatology department of CHRU de Nancy between January 2014 and December 2020 * Presenting with one or more infantile hemangioma

Exclusion criteria

\- Those whoes guardian does not want his data to be collected in this study

Design outcomes

Primary

Measure	Time frame	Description
Proportion of abortive hemangioma among infantile hemangioma	baseline	Proportion of abortive hemangioma among infantile hemangioma

Secondary

Measure	Time frame	Description
To compare the epidemiological characteristics between infantile hemangiomas and abortive hemangiomas : prematurity	baseline	Compare prematurity rates between infantile hemangiomas and abortive hemangiomas
To compare the epidemiological characteristics between infantile hemangiomas and abortive hemangiomas : birthweight	baseline	Compare birthweight between infantile hemangiomas and abortive hemangiomas
To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : localization	baseline	Compare localization between infantile hemangiomas and abortive hemangiomas
To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : treatment	baseline	le hemangiomas and abortive hemangiomaCompare treatment between infanti
To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : complications	baseline	Compare complications between infantile hemangiomas and abortive hemangioma
To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : size	baseline	Compare size (focal, extended or segmental) between infantile hemangiomas and abortive hemangioma
To compare the epidemiological characteristics between infantile hemangioma and abortive hemangioma : sex	baseline	Compare sex predominance between infantile hemangioma and abortive hemangioma
To study the evolution of abortive hemangioma : papules of proliferation	through study completion, an average of 4 years	Evaluation of the regression of the papules of proliferation between the stage of maximal proliferation and the last follow-up
To study the evolution of abortive hemangioma : telangiectasias	through study completion, an average of 4 years	Evaluation of the fading of telangiectasias between the stage of maximal proliferation and the last follow-up
To study the evolution of abortive hemangioma : halo of vasoconstriction	through study completion, an average of 4 years	Evaluation of the fading of the vasoconstricted halo between the stage of maximal proliferation and the last follow-up
To study the evolution of abortive hemangioma : areas of vasoconstriction	through study completion, an average of 4 years	Evaluation of the fading of vasoconstricted areas between the stage of maximal proliferation and the last follow-up
To study the evolution of abortive hemangioma : dilated veins	through study completion, an average of 4 years	Evaluation of the fading of dilated veins between the stage of maximal proliferation and the last follow-up
To study the evolution of abortive hemangioma : erythematous macule	through study completion, an average of 4 years	Evaluation of the fading of erythematous macule between the stage of maximal proliferation and the last follow-up

Countries

France

Outcome results